A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial

Jordan E Lake, Chi-Hong Tseng, Judith S Currier, Jordan E Lake, Chi-Hong Tseng, Judith S Currier

Abstract

Background: Visceral adiposity in the setting of HIV infection and antiretroviral therapy (ART) is not fully understood, and treatment options remain limited. Telmisartan, an angiotensin receptor blocker and partial PPAR-γ agonist, has been shown to decrease visceral fat and improve metabolic and inflammatory parameters in HIV-uninfected subjects.

Methods: HIV-infected subjects with HIV-1 RNA <50 copies/mL on ART and (women/men) waist circumference >94/95 cm or waist: hip ratio >0.88/0.94 received open-label telmisartan 40 mg po daily for 24 weeks. Adipose tissue (AT) volumes were quantified by L4-L5 single slice computed tomography. Metabolic and inflammatory markers were obtained fasting. Thirty-five subjects provided 80% power to detect a 10% 24-week decrease in visceral AT (VAT, two-sided α = 0.05).

Results: Thirty-five subjects enrolled and completed the protocol. At entry (median or %): age 49 years, 43% female, 77% non-white, 91% non-smokers, CD4+ T cell count 590 cells/mm(3), BMI 31 kg/m(2). AT responses were heterogeneous, with statistically significant losses of median (IQR) total (TAT, 2.9% (-9.8, 0.7), p = 0.03) and subcutaneous (SAT, -2.7% (-9.8, 1.1), p = 0.03) AT, but not VAT (-2.7% (-20.5, 14.2), p = 0.53). Significant decreases in waist circumference and waist:hip ratio occurred (both p<0.001) without BMI or weight changes. In an exploratory analysis, significant increases in TNF-α occurred among female subjects without changes in other inflammatory or metabolic markers. No related adverse events occurred.

Conclusions: Telmisartan was well tolerated. Small losses of AT from all depots were observed after 24 weeks of telmisartan therapy. Further study is needed to determine whether HIV-infected patients can receive metabolic benefits from telmisartan.

Trial registration: ClinicalTrials.gov NCT01088295.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Enrollment and disposition.
Figure 1. Enrollment and disposition.
AST = aspartate aminotransferase, ALT = alanine aminotransferase, ART = antiretroviral therapy.
Figure 2. 24-week changes in adipose tissue…
Figure 2. 24-week changes in adipose tissue volumes.
SAT = subcutaneous adipose tissue, VAT = visceral adipose tissue.
Figure 3. 24-week changes in adipose tissue…
Figure 3. 24-week changes in adipose tissue volumes by sex.
SAT = subcutaneous adipose tissue, VAT = visceral adipose tissue.

References

    1. Hadigan C, Meigs JB, Wilson PW, D’Agostino RB, Davis B, et al. (2003) Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 36: 909–916.
    1. Currier J, Scherzer R, Bacchetti P, Heymsfield S, Lee D, et al. (2008) Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 48: 35–43.
    1. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, et al. (2008) The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 48: 44–52.
    1. Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, et al. (2011) Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care 23: 929–938.
    1. Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, et al. (2005) Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 39: 44–54.
    1. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, et al. (2000) Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284: 472–477.
    1. Kohli R, Shevitz A, Gorbach S, Wanke C (2007) A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 8: 420–426.
    1. Caron M, Vigouroux C, Bastard JP, Capeau J (2009) Antiretroviral-Related Adipocyte Dysfunction and Lipodystrophy in HIV-Infected Patients: Alteration of the PPARgamma-Dependent Pathways. PPAR Res 2009: 507141.
    1. Lemoine M, Capeau J, Serfaty L (2009) PPAR and Liver Injury in HIV-Infected Patients. PPAR Res 2009: 906167.
    1. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, et al. (2002) Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163–170.
    1. Lo J, You SM, Canavan B, Liebau J, Beltrani G, et al. (2008) Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300: 509–519.
    1. Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, et al. (2008) Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 9: 254–268.
    1. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, et al. (2008) Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22: 1719–1728.
    1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, et al. (2007) Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357: 2359–2370.
    1. Shimabukuro M, Tanaka H, Shimabukuro T (2007) Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25: 841–848.
    1. Derosa G, Fogari E, D’Angelo A, Cicero AF, Salvadeo SA, et al. (2007) Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 32: 261–268.
    1. Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, et al. (2007) Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 30: 1205–1210.
    1. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, et al. (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertens 47: 1003–1009.
    1. Mori Y, Itoh Y, Tajima N (2007) Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 20: 431–436.
    1. Sharma AM (2006) The obese patient with diabetes mellitus: from research targets to treatment options. Am J Med 119: S17–23.
    1. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, et al. (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784–2791.
    1. Ohashi K, Ouchi N, Matsuzawa Y (2011) Adiponectin and hypertension. Am J Hypertens 24: 263–269.
    1. Nakagami H, Morishita R (2011) Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-gamma. Curr Vasc Pharmacol 9: 162–166.
    1. Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J (2012) Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Eur Rev Med Pharmacol Sci 16: 491–498.
    1. Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, et al. (2011) Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther 16: 639–645.
    1. Makino H, Haneda M, Babazono T, Moriya T, Ito S, et al. (2008) Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 31: 657–664.
    1. Shuster A, Patlas M, Pinthus JH, Mourtzakis M (2012) The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol 85: 1–10.
    1. Falutz JAH, Marsolais C, Morin J, Mamputu JC, Soulban G, Grinspoon S (2011) Metabolic Risk Factors in Responders to Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Excess Abdominal Fat. Antivir Ther 16: A29.
    1. Kubik M, Chudek J, Adamczak M, Wiecek A (2012) Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension. Kidney Blood Press Res 35: 281–289.
    1. Huang GZ, Tang YH, Wang BY, Zhang B, Hu TJ, et al. (2011) Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J 32: 1017–1021.
    1. Boccara F, Auclair M, Cohen A, Lefevre C, Prot M, et al. (2010) HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther 15: 363–375.
    1. Meade TW, Imeson JD, Gordon D, Peart WS (1983) The epidemiology of plasma renin. Clin Sci (Lond) 64: 273–280.
    1. Chappell MC (2010) Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation. Arthritis Res Ther 12: 128.
    1. Walther T, Stepan H (2007) Agonist autoantibodies against the angiotensin AT1 receptor in renal and hypertensive disorders. Curr Hypertens Rep 9: 128–132.
    1. Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, et al. (2011) Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart 97: 479–484.
    1. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
    1. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, et al. (2010) Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 55: 316–322.
    1. Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H (2003) C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 32: 210–214.
    1. Fichtenbaum CJ (2011) Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep 13: 94–101.
    1. Barbaro G (2007) Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des 13: 2208–2213.
    1. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56: 1010–1013.
    1. Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G (2007) Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 13: 2169–2175.
    1. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H (2003) Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS 17: 521–530.
    1. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, et al. (2010) Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 7: e1000384.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir